Skip to Content

Recro Pharma, Inc. (NASDAQ: REPH)

Securities Class Action

  • Date:
  • 5/13/2020
  • Company Name:
  • Recro Pharma, Inc.
  • Stock Symbol:
  • REPH
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

NEW YORK, May 13, 2020 –Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Recro Pharma, Inc. (NASDAQ: REPH) on behalf of Recro Pharma stockholders. Our investigation concerns whether Recro Pharma has violated the federal securities laws and/or engaged in other unlawful business practices.

On May 11, 2020, Recro Pharma reported worse-than-expected financial results for the first quarter and revised its 2020 revenue guidance down from a range of $97-100 million to a range of $80-85 million. In revising its guidance, Recro Pharma cited several factors, including: (i) increased competition by one of the Company’s key customer’s competitors, (ii) slower than expected new business growth primarily attributable to COVID-19, and (iii) notifications by two customers of discontinuations for two commercial product lines.

On this news, Recro Pharma’s share price fell $3.34, or 39.6%,to close at $8.42 per share on May 11, 2020.

If you purchased or otherwise acquired Recro Pharma shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact  Melissa Fortunato or Marion Passmore or by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Recro Pharma. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: